Search hospitals > Illinois > Peoria
Saint Jude Midwest Affiliate
Claim this profilePeoria, Illinois 61602
Global Leader in Tumors
Global Leader in Leukemia
Conducts research for Brain Tumor
Conducts research for Sarcoma
Conducts research for Lymphoma
172 reported clinical trials
3 medical researchers
Summary
Saint Jude Midwest Affiliate is a medical facility located in Peoria, Illinois. This center is recognized for care of Tumors, Leukemia, Brain Tumor, Sarcoma, Lymphoma and other specialties. Saint Jude Midwest Affiliate is involved with conducting 172 clinical trials across 312 conditions. There are 3 research doctors associated with this hospital, such as Jaime M. Libes, Amber M. D'Souza, and Prerna Kumar.Area of expertise
1Tumors
Global LeaderStage IV
Stage I
Stage II
2Leukemia
Global LeaderStage II
NTRK1 positive
NTRK positive
Top PIs
Jaime M. LibesSaint Jude Midwest Affiliate7 years of reported clinical research
Expert in Tumors
Expert in Cancer
56 reported clinical trials
99 drugs studied
Amber M. D'SouzaSaint Jude Midwest Affiliate7 years of reported clinical research
Expert in Tumors
Expert in Cancer
37 reported clinical trials
83 drugs studied
Prerna KumarSaint Jude Midwest Affiliate2 years of reported clinical research
Expert in Tumors
Expert in Cancer
35 reported clinical trials
85 drugs studied
Clinical Trials running at Saint Jude Midwest Affiliate
Germ Cell Tumors
Osteosarcoma
Brain Tumor
Langerhans Cell Histiocytosis
Rhabdomyosarcoma
Non-Hodgkin's Lymphoma
Tumors
Neuroectodermal Tumors
Rhabdoid Tumor
Hepatoblastoma
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Chemotherapy + Radiation Therapy
for Brain Cancer
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT.
Recruiting1 award Phase 2
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Saint Jude Midwest Affiliate?
Saint Jude Midwest Affiliate is a medical facility located in Peoria, Illinois. This center is recognized for care of Tumors, Leukemia, Brain Tumor, Sarcoma, Lymphoma and other specialties. Saint Jude Midwest Affiliate is involved with conducting 172 clinical trials across 312 conditions. There are 3 research doctors associated with this hospital, such as Jaime M. Libes, Amber M. D'Souza, and Prerna Kumar.